Semzuvolimab

Semzuvolimab is an experimental cancer drug developed by Innovent Biologics and Eli Lilly and Company. It is a monoclonal antibody designed to inhibit PD-1, a protein that plays a major role in suppressing the immune system. By blocking PD-1, semzuvolimab may help the immune system recognize and attack cancer cells.

Development and Clinical Trials[edit | edit source]

Semzuvolimab is currently in clinical trials for the treatment of various types of cancer. In a Phase 1 trial, the drug showed promising results in patients with advanced solid tumors. The trial found that semzuvolimab was well-tolerated and demonstrated anti-tumor activity.

Innovent and Eli Lilly are also conducting a Phase 3 trial to evaluate the efficacy and safety of semzuvolimab in combination with chemotherapy in patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma.

Mechanism of Action[edit | edit source]

Semzuvolimab works by binding to PD-1, a protein found on the surface of certain immune cells. PD-1 acts as a "brake" on the immune system, preventing it from attacking normal cells. However, some cancer cells can exploit this mechanism to avoid being targeted by the immune system. By blocking PD-1, semzuvolimab can potentially enhance the body's immune response against cancer cells.

Potential Side Effects[edit | edit source]

As with any drug, semzuvolimab may cause side effects. In clinical trials, the most common side effects were fatigue, decreased appetite, and nausea. Serious side effects, including immune-related adverse events, were also reported.

Future Prospects[edit | edit source]

If successful in clinical trials, semzuvolimab could offer a new treatment option for patients with advanced cancers. However, further research is needed to fully understand the drug's efficacy and safety profile.

Semzuvolimab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.